These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 37959304)
21. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382 [TBL] [Abstract][Full Text] [Related]
22. GP2017: An Adalimumab Biosimilar. Heo YA BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599 [TBL] [Abstract][Full Text] [Related]
23. Biosimilars in ulcerative colitis: When and for who? Ilias A; Gonczi L; Kurti Z; Lakatos PL Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302 [TBL] [Abstract][Full Text] [Related]
25. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. Ribaldone DG; Tribocco E; Rosso C; Armandi A; Vernero M; Bugianesi E; Astegiano M; Saracco GM; Caviglia GP J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362184 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study. Wang F; Li X; Shi Y; Zhou H; Yang G; Li R; Wu T; Liang J Front Pharmacol; 2023; 14():1259183. PubMed ID: 37908975 [No Abstract] [Full Text] [Related]
27. Biosimilar biological drugs in the treatment of inflammatory bowel diseases. Kaniewska M; Eder P; Gąsiorowska A; Gonciarz M; Kierkuś J; Małecka-Panas E; Rydzewska G Prz Gastroenterol; 2019; 14(4):223-227. PubMed ID: 31988667 [TBL] [Abstract][Full Text] [Related]
28. Real-world data on the infliximab biosimilar CT-P13 (Remsima Huguet JM; Cortés X; Bosca-Watts MM; Aguas M; Maroto N; Martí L; Amorós C; Paredes JM World J Clin Cases; 2021 Dec; 9(36):11285-11299. PubMed ID: 35071559 [TBL] [Abstract][Full Text] [Related]
29. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR; Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564 [TBL] [Abstract][Full Text] [Related]
30. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence. Dipasquale V; Cicala G; Spina E; Romano C Front Pharmacol; 2022; 13():846151. PubMed ID: 35370732 [No Abstract] [Full Text] [Related]
31. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T; Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404 [TBL] [Abstract][Full Text] [Related]
32. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade. Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103 [TBL] [Abstract][Full Text] [Related]
33. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe. Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522 [TBL] [Abstract][Full Text] [Related]
34. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Scott FI; Lichtenstein GR Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting. Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364 [TBL] [Abstract][Full Text] [Related]
36. Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases. Somers M; Bossuyt P; Ferrante M; Peeters H; Baert F J Crohns Colitis; 2020 Jun; 14(5):680-685. PubMed ID: 31875891 [TBL] [Abstract][Full Text] [Related]